Belfast Telegraph

Drug giant curing collapse in sales

Glaxosmithkline insisted it is well placed to reverse falling sales after it highlighted a portfolio of 30 drugs within sight of release.

CEO Sir Andrew Witty said there were "increasing signs that we can replenish our pipeline", offsetting fears over the impact of cheaper competition and austerity measures. Three new products were approved in 2011 and four new medicines are ready to file.